Laboratory effect on platelet activity within 24 h of the first 300-mg oral dose of aspirin given in hospital during the acute phase of ischemic cerebral events

Cerebrovascular Diseases

Volumn 33, Issue 6, 2012, Pages 574-578

  Richard, S ^a   Toussaint Hacquard, M ^b   Fay, R ^a   Lacour, J C ^a   Ducrocq, X ^a   Lecompte, T ^b  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b CHU NANCY BRABOIS   (France)

Author keywords

Aspirin; Ischemic stroke; Platelet

Indexed keywords

ACETYLSALICYLIC ACID; COLLAGEN TYPE 2; HEMOGLOBIN; THROMBOXANE A2; THROMBOXANE B2;

ADULT; AGED; ARTICLE; BRAIN ISCHEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; LEUKOCYTE COUNT; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; SMOKING; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; TRANSIENT ISCHEMIC ATTACK;

ACUTE DISEASE; ADMINISTRATION, ORAL; AGED; ASPIRIN; BLOOD PLATELETS; BRAIN ISCHEMIA; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; THROMBOXANES; TIME FACTORS;

EID: 84862243369     PISSN: 10159770     EISSN: 14219786     Source Type: Journal    
DOI: 10.1159/000338291     Document Type: Article

References (24)

1. Patrono C, Baigent C, Hirsh J, Roth G: Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 199-233.
2. Bousser MG: Antithrombotic agents in the prevention of ischemic stroke. Cerebrovasc Dis 2009; 27: 12-19.
3. Catella-Lawson F: Vascular biology of thrombosis: platelet-vessel wall interactions and aspirin effects. Neurology 2001; 57: 5-7.
4. Hohlfeld T, Weber AA, Junghans U, Schumacher M, Boucher M, Schror K, Siebler M: Variable platelet response to aspirin in patients with ischemic stroke. Cerebrovasc Dis 2007; 24: 43-50. (Pubitemid 47026140)
5. Sandercock PA, Counsell C, Gubitz GJ, Tseng MC: Antiplatelet therapy for acute ischaemic stroke. Cochrane Database Syst Rev 2008, p CD000028.
6. Schwammenthal Y, Tsabari R, Shenkman B, Schwartz R, Matetzky S, Lubetsky A, Orion D, Israeli-Korn S, Chapman J, Savion N, Varon D, Tanne D: Aspirin responsiveness in acute brain ischaemia: association with stroke severity and clinical outcome. Cerebrovasc Dis 2008; 25: 355-361. (Pubitemid 351555860)
7. International Stroke Trial Collaborative Group: The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997; 349: 1569-1581.
8. CAST (Chinese Acute Stroke Trial) Collaborative Group: CAST: randomised placebocontrolled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997; 349: 1641-1649.
9. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O'Fallon WM, Wiebers DO: Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975. through 1989. Neurology 1998; 50: 208-216.
10. Coull AJ, Lovett JK, Rothwell PM, Oxford Vascular Study: Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services. BMJ 2004; 328: 326.
11. Henry P, Vermillet A, Boval B, Guyetand C, Petroni T, Dillinger JG, Sideris G, Sollier CB, Drouet L: 24-hour time-dependent aspirin efficacy in patients with stable coronary artery disease. Thromb Haemost 2011; 105: 336-344.
12. Guthikonda S, Lev EI, Patel R, Delao T, Bergeron AL, Dong JF, Kleiman NS: Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin. J Throm Haemost 2007; 5: 490-496. (Pubitemid 46680680)
13. Lucas AR, Korol R, Pepine CJ: Inflammation in atherosclerosis: some thoughts about acute coronary syndromes. Circulation 2006; 113: 728-732.
14. Patrignani P: Aspirin insensitive eicosanoid biosynthesis in cardiovascular disease. Thromb Res 2003; 110: 281-286. (Pubitemid 37329826)
15. Cipollone F, Rocca B, Patrono C: Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol 2004; 24: 246-255. (Pubitemid 38197575)
16. Dore S, Otsuka T, Mito T, Sugo N, Hand T, Wu L, Hurn PD, Traystman RJ, Andreasson K: Neuronal overexpression of cyclooxygenase-2 increases cerebral infarction. Ann Neurol 2003; 54: 155-162. (Pubitemid 36909614)
17. Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, Luzak B, Kropiwnicka A, Drzewoski J: Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin): its relation to metabolic control. Thromb Res 2004; 113: 101-113. (Pubitemid 38534487)
18. Momary KM, Shapiro NL, Brace LD, Shord SS, Grossi E, Viana MA, Helgason CM, Nutescu EA, Cavallari LH: Influence of cyclooxygenase-1 genotype on ex vivo aspirin response in patients at risk for stroke. Cerebrovasc Dis 2009; 27: 509-518.
19. Maree AO, Curtin RJ, Chubb A, Dolan C, Cox D, O'Brien J, Crean P, Shields DC, Fitzgerald DJ: Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J Thromb Haemost 2005; 3: 2340-2345. (Pubitemid 41727215)
20. Hillarp A, Palmqvist B, Lethagen S, Villoutreix BO, Mattiasson I: Mutations within the cyclooxygenase-1 gene in aspirin non-responders with recurrence of stroke. Thromb Res 2003; 112: 275-283. (Pubitemid 38373757)
21. King A, Bath PM, Markus HS: Clopidogrel versus dipyridamole in addition to aspirin in reducing embolization detected with ambulatory transcranial Doppler: a randomized trial. Stroke 2011; 42: 650-655.
22. Hankey GJ, Eikelboom JW: Adding aspirin to clopidogrel after TIA and ischemic stroke: benefits do not match risks. Neurology 2005; 64: 1117-1121.
23. Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, de Cordoüe A, Fratacci MD, PERFORM Study Investigators: Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet 2011; 377: 2013-2022.
24. Bal Dit Sollier C, Crassard I, Simoneau G, Bergmann JF, Bousser MG, Drouet L: Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. Cerebrovasc Dis 2009; 28: 505-513.